High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Not Recruiting

Trial ID: NCT01973517


Feraheme (ferumoxytol) is FDA-approved for iron supplementation and is composed of iron oxide nanoparticles classified among the ultra-small superparamagnetic iron oxides (USPIO). In this project we hypothesize that Feraheme could become a sensitive and specific marker of active inflammation in multiple sclerosis. We will explore this hypothesis taking advantage of ultra high field strength (7T) MRI to further increase the effectiveness of the contrast agent Feraheme at revealing inflammatory activity.

Official Title

7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Stanford Investigator(s)


Inclusion Criteria:

   - Patients will be included if they are at least 18 years old and meet the revised
   diagnostic criteria for multiple sclerosis, relapsing remitting type.

   - Patients will be included based on MR evidence of disease activity after Gadolinium
   (enhanced lesion) on a previous screening MR in the previous 3 weeks days before
   Feraheme administration.

Exclusion Criteria:

   - Children (age < 18)

   - Those who lack decision-making capability

   - Contraindication to MRI such as pacemaker, other MR-incompatible metal implants or

   - Known allergy to dextran or drugs containing iron salts or any previous history of
   severe allergic reactions

   - Evidence of iron overload such as hemochromatosis or other hematologic disorders that
   imply iron level superior to the normal level.

   - Pregnancy or breast feeding.

   - History of renal disease or estimated glomerular filtration rate (eGFR) using the
   Modification of Diet in Renal Disease (MDRD) <40ml/min/1.73m?


drug: Feraheme

drug: Gadolinium-based contrast

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305